Compare Microchip Technology Inc. (MCHP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs BIO-TECHNE Corp — how do they compare? Microchip Technology Inc. trades at $83.12 (market cap $43.72B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Microchip Technology Inc. is far larger — about 3.9× BIO-TECHNE Corp's market cap, and Microchip Technology Inc. pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| MCHP | TECH | |
|---|---|---|
Market Cap | $43.72B | $11.16B |
Sector | Technology | Health |
52-Week High | $102.97 | $72.12 |
52-Week Low | $49.02 | $43.31 |
Enterprise Value | $49.01B | $11.24B |
Dividend Yield | 2.26% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
